Portal de Periódicos da CAPES

Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome

2009; Dustri-Verlag; Volume: 72; Issue: 07 Linguagem: Inglês

10.5414/cnp72069

0301-0430

Yukako Sawara, Mitsuyo Itabashi, Chiari Kojima, Hidehiro Tabata, Daigo Kamei, Kunio Kawanishi, Takahito Moriyama, Hidekazu Sugiura, Misao Tsukada, Takashi Takei, Tetsuya Ogawa, Tetsuya Yoshida, Junko Arai, Keiko Uchida, K. Tsuchiya, Kosaku Nitta,

Amyloidosis: Diagnosis, Treatment, Outcomes

Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.